CN109790211B - 抗kras-g12d t细胞受体 - Google Patents

抗kras-g12d t细胞受体 Download PDF

Info

Publication number
CN109790211B
CN109790211B CN201780059356.4A CN201780059356A CN109790211B CN 109790211 B CN109790211 B CN 109790211B CN 201780059356 A CN201780059356 A CN 201780059356A CN 109790211 B CN109790211 B CN 109790211B
Authority
CN
China
Prior art keywords
seq
leu
ser
val
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780059356.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN109790211A (zh
Inventor
埃里克·特兰
保罗·F·罗宾斯
史蒂文·A·罗森伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Priority to CN202410214235.4A priority Critical patent/CN118063591A/zh
Publication of CN109790211A publication Critical patent/CN109790211A/zh
Application granted granted Critical
Publication of CN109790211B publication Critical patent/CN109790211B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
CN201780059356.4A 2016-08-02 2017-07-31 抗kras-g12d t细胞受体 Active CN109790211B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410214235.4A CN118063591A (zh) 2016-08-02 2017-07-31 抗kras-g12d t细胞受体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662369883P 2016-08-02 2016-08-02
US62/369,883 2016-08-02
PCT/US2017/044615 WO2018026691A1 (en) 2016-08-02 2017-07-31 Anti-kras-g12d t cell receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410214235.4A Division CN118063591A (zh) 2016-08-02 2017-07-31 抗kras-g12d t细胞受体

Publications (2)

Publication Number Publication Date
CN109790211A CN109790211A (zh) 2019-05-21
CN109790211B true CN109790211B (zh) 2024-03-26

Family

ID=59564253

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780059356.4A Active CN109790211B (zh) 2016-08-02 2017-07-31 抗kras-g12d t细胞受体
CN202410214235.4A Pending CN118063591A (zh) 2016-08-02 2017-07-31 抗kras-g12d t细胞受体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410214235.4A Pending CN118063591A (zh) 2016-08-02 2017-07-31 抗kras-g12d t细胞受体

Country Status (20)

Country Link
US (6) US10611816B2 (enExample)
EP (2) EP4159751A1 (enExample)
JP (4) JP6993402B2 (enExample)
KR (1) KR102527052B1 (enExample)
CN (2) CN109790211B (enExample)
AU (2) AU2017306038B2 (enExample)
CA (1) CA3032870A1 (enExample)
DK (1) DK3494133T3 (enExample)
ES (1) ES2928051T3 (enExample)
HR (1) HRP20221183T1 (enExample)
HU (1) HUE060121T2 (enExample)
IL (2) IL264425B2 (enExample)
LT (1) LT3494133T (enExample)
PL (1) PL3494133T3 (enExample)
PT (1) PT3494133T (enExample)
RS (1) RS63615B1 (enExample)
SG (2) SG10201913959WA (enExample)
SI (1) SI3494133T1 (enExample)
SM (1) SMT202200379T1 (enExample)
WO (1) WO2018026691A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017306038B2 (en) * 2016-08-02 2023-06-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-KRAS-G12D T cell receptors
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
JP7256794B2 (ja) 2017-09-20 2023-04-12 アメリカ合衆国 変異型ｒａｓに対するｈｌａクラスｉｉ拘束性ｔ細胞受容体
FI3692140T3 (fi) 2017-10-05 2023-10-11 Us Health Menetelmiä solujen laajentamiseksi selektiivisesti ekspressoiden TCR:ää vakiolla muriinialueella
US12246067B2 (en) 2018-06-19 2025-03-11 Biontech Us Inc. Neoantigens and uses thereof
WO2020154617A1 (en) * 2019-01-25 2020-07-30 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting mutant ras
CA3130618A1 (en) * 2019-02-20 2020-08-27 Fred Hutchinson Cancer Research Center Binding proteins specific for ras neoantigens and uses thereof
CN110172089B (zh) * 2019-06-11 2020-01-07 北京鼎成肽源生物技术有限公司 一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用
CN112110995A (zh) * 2019-06-19 2020-12-22 上海交通大学医学院 肿瘤新抗原多肽及其用途
CN112760290A (zh) * 2019-10-21 2021-05-07 郑州大学 携带突变的肿瘤驱动基因的干细胞及其用途
CN112759641B (zh) * 2019-11-01 2023-01-20 香雪生命科学技术（广东）有限公司 一种识别Kras G12V的高亲和力TCR
WO2021092223A1 (en) * 2019-11-05 2021-05-14 Board Of Regents, The University Of Texas System Hla restricted hormad1 t cell receptors and uses thereof
CN115244173A (zh) 2019-12-20 2022-10-25 英研生物(英国)有限公司 用于分离肿瘤浸润淋巴细胞的装置及方法及其用途
JP7614659B2 (ja) * 2019-12-30 2025-01-16 ブリスター イムノテック リミテッド 強化されたｔ細胞受容体ｓｔａｒ及びその用途
EP4178976A1 (en) * 2020-07-13 2023-05-17 The United States of America, as represented by the Secretary, Department of Health and Human Services Hla class ii?restricted drb t cell receptors against ras with g12d mutation
GB2615010A (en) * 2020-10-02 2023-07-26 Us Health HLA class II-restricted DQ T cell receptors against RAS with G13D mutation
AU2021381384A1 (en) * 2020-11-20 2023-06-22 Think Therapeutics, Inc. Compositions and methods for optimized peptide vaccines
AU2021388167A1 (en) * 2020-11-25 2023-07-06 Geneius Biotechnology, Inc. Antigen specific t cells and methods of making and using same
KR20230150336A (ko) 2021-02-25 2023-10-30 알로노스 테라퓨틱스 인코포레이티드 폴리시스트론 발현 카세트를 포함하는 재조합 벡터 및 이의 사용 방법
EP4334361A1 (en) 2021-05-05 2024-03-13 Immatics Biotechnologies GmbH Antigen binding proteins specifically binding prame
WO2023150562A1 (en) 2022-02-01 2023-08-10 Alaunos Therapeutics, Inc. Methods for activation and expansion of t cells
CN114920823B (zh) * 2022-05-27 2023-10-17 重庆医科大学 Tcr或其抗原结合片段及其应用
CN119744173A (zh) * 2022-07-22 2025-04-01 得克萨斯大学体系董事会 用于过继免疫疗法的具有增强功能的表达cd3的自然杀伤细胞
CN115850444B (zh) * 2022-09-15 2025-01-28 重庆医科大学 Tcr或其抗原结合片段及其应用
CN117777270B (zh) * 2022-09-29 2025-04-25 广州医科大学 一种t细胞受体(tcr)及其用途
EP4633665A2 (en) * 2022-12-13 2025-10-22 BioNTech US Inc. T cell receptor constructs and uses thereof
WO2025006196A1 (en) 2023-06-28 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting ras with g12d, g12r, or g12v mutation
CN120157754A (zh) * 2023-12-14 2025-06-17 新景智源生物科技(苏州)有限公司 Kras_g12d突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016085904A1 (en) * 2014-11-26 2016-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mutated kras t cell receptors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776459A (en) * 1989-07-19 1998-07-07 Connetics Corporation TCR V beta 5 peptides
US20020150891A1 (en) * 1994-09-19 2002-10-17 Leroy E. Hood Diagnostic and therapeutic compositions and methods which utilize the t cell receptor beta gene region
US7709002B1 (en) 1996-04-19 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes
GB2328689A (en) 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
ES2602145T3 (es) 2002-09-06 2017-02-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inmunoterapia con linfocitos específicos de antígeno seleccionados in vitro después de quimioterapia supresora de linfocitos no mieloablativa
CA2674445C (en) 2007-01-12 2016-06-07 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Gp100-specific t cell receptors and related materials and methods of use
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
EP2618835B1 (en) 2010-09-20 2017-07-05 BioNTech Cell & Gene Therapies GmbH Antigen-specific t cell receptors and t cell epitopes
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
SI2755997T1 (sl) 2011-09-15 2018-11-30 The United States of America, as represented by Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health T-celični receptorji, ki prepoznajo HLA-A1- ali HLA-CW7-omejeni mage
CA2853645A1 (en) * 2011-11-30 2013-06-06 National Cancer Center Induced malignant stem cells
KR20160013049A (ko) * 2013-06-03 2016-02-03 노파르티스 아게 항-pd-l1 항체 및 mek 억제제 및/또는 braf 억제제의 조합물
GB201313377D0 (en) * 2013-07-26 2013-09-11 Adaptimmune Ltd T cell receptors
GB201314404D0 (en) 2013-08-12 2013-09-25 Immunocore Ltd T Cell Receptors
US10556940B2 (en) 2015-09-15 2020-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing HLA-Cw8 restricted mutated KRAS
AU2017306038B2 (en) * 2016-08-02 2023-06-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-KRAS-G12D T cell receptors
WO2025006196A1 (en) 2023-06-28 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting ras with g12d, g12r, or g12v mutation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016085904A1 (en) * 2014-11-26 2016-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mutated kras t cell receptors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors;Qiong J Wang,et al;《Cancer Immunol Res.》;20151223;第4卷(第3期);第204-214页 *

Also Published As

Publication number Publication date
EP3494133A1 (en) 2019-06-12
PL3494133T3 (pl) 2022-11-21
SMT202200379T1 (it) 2022-11-18
AU2017306038B2 (en) 2023-06-22
CA3032870A1 (en) 2018-02-08
DK3494133T3 (da) 2022-09-19
US20240209059A1 (en) 2024-06-27
US12391742B2 (en) 2025-08-19
JP7413338B2 (ja) 2024-01-15
EP4159751A1 (en) 2023-04-05
US20250340611A1 (en) 2025-11-06
IL301894B2 (en) 2025-02-01
JP2022050400A (ja) 2022-03-30
IL264425B1 (en) 2023-05-01
SG11201900654QA (en) 2019-02-27
HRP20221183T1 (hr) 2022-12-09
RS63615B1 (sr) 2022-10-31
CN109790211A (zh) 2019-05-21
IL264425A (enExample) 2019-03-31
JP2019527555A (ja) 2019-10-03
PT3494133T (pt) 2022-09-28
JP2024045139A (ja) 2024-04-02
IL264425B2 (en) 2023-09-01
KR20190064566A (ko) 2019-06-10
WO2018026691A1 (en) 2018-02-08
HUE060121T2 (hu) 2023-01-28
KR102527052B1 (ko) 2023-04-27
US20210300988A1 (en) 2021-09-30
JP7649370B2 (ja) 2025-03-19
JP2025090690A (ja) 2025-06-17
US20190177395A1 (en) 2019-06-13
JP6993402B2 (ja) 2022-02-03
AU2023233125B2 (en) 2025-10-16
AU2017306038A1 (en) 2019-02-14
IL301894A (en) 2023-06-01
ES2928051T3 (es) 2022-11-15
LT3494133T (lt) 2022-12-12
US11208456B2 (en) 2021-12-28
US11897933B2 (en) 2024-02-13
US11840561B2 (en) 2023-12-12
EP3494133B1 (en) 2022-07-06
CN118063591A (zh) 2024-05-24
SI3494133T1 (sl) 2022-11-30
US20200247869A1 (en) 2020-08-06
SG10201913959WA (en) 2020-03-30
US10611816B2 (en) 2020-04-07
US20220089677A1 (en) 2022-03-24
IL301894B1 (en) 2024-10-01
AU2023233125A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
JP7649370B2 (ja) 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体
AU2021200833B2 (en) T Cell receptors recognizing HLA-Cw8 restricted mutated KRAS
EP3688027B1 (en) T cell receptors recognizing mutated p53
JP7635165B2 (ja) ｐ５３におけるＲ１７５Ｈ又はＹ２２０Ｃ変異を認識するＴ細胞受容体
HK40008470A (en) Anti-kras-g12d t cell receptors
HK40009637B (en) Anti-kras-g12d t cell receptors
HK40009637A (en) Anti-kras-g12d t cell receptors
HK40008470B (zh) 抗kras-g12d t细胞受体
HK1257902B (en) T cell receptors recognizing hla-cw8 restricted mutated kras

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40008470

Country of ref document: HK

CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: Eric Tran

Inventor after: Paul F. Robbins

Inventor after: Steven A. Rosenberg

Inventor before: Eric Tran

Inventor before: Lu Yongcheng

Inventor before: Anna Passeto

Inventor before: Paul F. Robbins

Inventor before: Steven A. Rosenberg

Inventor before: Zheng Zhili

GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment